Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Rhea-AI Summary
Prelude Therapeutics (Nasdaq: PRLD) priced an underwritten offering of 18,018,014 shares at $4.44 per share and pre-funded warrants for up to 2,252,252 shares at $4.4399 each, generating approximately $90.0 million in gross proceeds.
The offering is expected to close on or about April 21, 2026, was led by RA Capital, and the company intends to use net proceeds for general corporate purposes, including research and clinical development.
Positive
- Gross proceeds of approximately $90.0 million
- Offering led by new investor RA Capital, signaling institutional demand
- Included pre-funded warrants for up to 2,252,252 shares to accommodate certain investors
Negative
- Issuance of 18,018,014 shares may be dilutive to existing shareholders
- Actual net proceeds will be less than $90.0 million after underwriting discounts, commissions, and expenses
News Market Reaction – PRLD
In the Apr 20 session, PRLD gained 1.58%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.7% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Executive appointment | Positive | +25.4% | New Chief Medical Officer joins to lead clinical strategy and programs. |
| Mar 17 | Preclinical data update | Positive | -9.0% | AACR preclinical poster shows complete tumor regressions for PRT13722. |
| Mar 10 | Earnings and outlook | Positive | +16.5% | Full-year 2025 results show lower expenses and narrowed net loss. |
| Feb 03 | Regulatory clearance | Positive | +12.8% | FDA clears IND for PRT12396 enabling Phase 1 study initiation. |
| Dec 06 | Conference data presentation | Positive | +0.0% | ASH 2025 preclinical data on JAK2 and mCALR-targeted degrader programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been followed by positive moves, especially around pipeline and corporate updates, with one notable negative reaction to a preclinical data poster and a flat response to ASH data.
Over the last six months, PRLD has reported multiple pipeline and corporate milestones. FDA IND clearance for PRT12396 in myeloproliferative neoplasms on Mar 10, 2026 was followed by a 12.81% gain. Full-year 2025 results on the same date, highlighting lower R&D and G&A expenses and a narrowed $99.5M net loss, coincided with a 16.5% rise. Subsequent AACR and CMO appointment news saw mixed reactions, showing that not all positive scientific updates translate into immediate price strength.
Key Terms
underwritten offering financial
pre-funded warrants financial
exercise price financial
joint book-running managers financial
registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the “Common Stock”) at a price of
The offering was led by new investor RA Capital Management with participation from Soleus Capital, as well as other new and existing healthcare dedicated investors.
Goldman Sachs & Co. LLC, Evercore ISI and Citizens Capital Markets are acting as the joint book-running managers for the offering.
The Company intends to use the net proceeds from the offering primarily for general corporate purposes, which may include funding research, preclinical and clinical development of its product candidates, increasing its working capital and capital expenditures.
A registration statement on Form S-3 relating to these securities was filed with the Securities and Exchange Commission (“SEC”) on May 30, 2024, and was declared effective by the SEC on June 10, 2024. A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. These documents will be available on the SEC’s website at http://www.sec.gov. You can also obtain the prospectus supplement and accompanying prospectus by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; or Citizens JMP Securities, LLC, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111, by telephone at (415) 835-8985, or by email at syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Prelude Therapeutics
Prelude is a leading clinical-stage precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Its pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. Prelude is leveraging its expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. Prelude is on a mission to extend the promise of precision medicine to every cancer patient in need.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the satisfaction of customary closing conditions relating to the offering and sale of securities, Prelude’s ability to complete the offering, the anticipated gross proceeds from the offering and the intended use of the proceeds from the offering. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude’s ability to fund development activities and achieve development goals, Prelude’s ability to protect intellectual property, and other risks and uncertainties described under the heading “Risk Factors” in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the SEC. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated
484.639.7235
rdoody@preludetx.com
